Cambridge Healthtech Institute’s Second Annual

Display of Antibodies

Empowering Novel Biologics

2-3 November 2015


New technologies are poised to change the gold standard for display methodologies in identifying and isolating protein ligands with the potential to become therapeutic antibodies. The full spectrum from discovery to clinical applications will be covered. Topics will include antibody discovery, library construction, targeting membrane proteins and intracellular targets, generating novel constructs including antibody-drug conjugates, bispecific antibodies and alternative scaffolds, and enhancements in eukaryotic display. This meeting is an essential event for anyone working in the area of protein engineering. Join us in November to network with your peers and be inspired by progress in the field.

Preliminary Agenda


PLENARY KEYNOTE SESSION

Protein Engineering for New Modes of Actions and New Targets

Andreas G. Plückthun, Ph.D., Professor & Director, Biochemistry, University of Zurich

Targeting Ion Channels

Tristan J. Vaughan, Ph.D., Senior Director, Antibody Discovery & Protein Engineering, MedImmune Ltd.

Current and Future Trends in Antibody Therapeutics

Paul W.H.I. Parren, Ph.D., Senior Vice President & Scientific Director, Preclinical Development & Research, Genmab


EUKARYOTIC DISPLAY

Use of Adimab Technology for Yeast Display

Trevor A. Wattam, Ph.D., Manager, Biopharm Discovery Group, GlaxoSmithKline

Construction and Use of Large Antibody Libraries in Mammalian Cells

John McCafferty, Ph.D., Co-Founder, Director and CEO, IONTAS Ltd.


NEW TECHNOLOGIES

DNA-Encoded Chemical Libraries for the Isolation of High-Affinity Binding Ligands: An Alternative to Antibodies

Dario Neri, Ph.D., Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich)

Deep Microfluidic Screening for Discovery of Rare Antibodies with Optimal Properties

William S. Somers, Ph.D., Vice President, Global Biotherapeutic Technologies, Pfizer


USING DISPLAY FOR IMMUNOTHERAPY APPLICATIONS

Engineered T-Cell Receptors as Tools for the Study of Peptide–MHC Interactions

Geir Åge Løset, Ph.D., Researcher, Centre for Immune Regulation and Department of Biosciences, University of Oslo; CSO, Nextera AS

Multiscale, Multimodal in vivo Imaging of CAR T-Cell Therapies

Adam Badar, Ph.D., Head, Preclinical Nuclear Medicine, Centre for Advanced Biomedical Imaging (CABI), University College London


ANTIBODY GENERATION

Next-Generation Sequencing of Phage Display Panning Output Pools to Guide Antibody Lead Selection

Stefan Ewert, Ph.D., Senior Investigator, NIBR Biologics Center, Novartis Pharma AG

Call of the Wild: A New Generation of Antibody Discovery from Natural Sources

Jacob Glanville, CSO, Distributed Bio LLC

Phenotypic Screening for Novel Antibody Targets in the Tumour Microenvironment

Ralph R. Minter, Ph.D., Fellow, Antibody Discovery and Protein Engineering, MedImmune Ltd.


TARGETING DIFFICULT ANTIGENS WITH DISPLAY TECHNOLOGIES

Dissecting and Engineering Phage-Displayed Membrane Proteins

Gregory A. Weiss, Ph.D., Professor, Chemistry and Molecular Biology & Biochemistry, University of California, Irvine

Computer Guided Design of Antibodies Combined with Display Technologies to Identify Antibodies to Difficult Targets

Yanay Ofran, Ph.D., Founder, Biolojic Design Ltd.

Targeted Modulation of hERG Channel Activity with scFv Antibody Fragments

Carol A. Harley, Ph.D., Research Scientist, Structural Biochemistry, IBMC- Instituto de Biologia Molecular e Celular




For more details on the conference, please contact: 

Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
Tel: +1 781-972-5464
Email: clingham@healthtech.com 

For partnering and sponsorship information, please contact: 

Carol Dinerstein,
Director, Business Development
Cambridge Healthtech Institute
Tel: 1 781-972-5471
Email: dinerstein@healthtech.com 

Jason Gerardi
Business Development Manager
Cambridge Healthtech Institute
Tel: 781-972-5452
Email: jgerardi@healthtech.com